CD274 and esophageal squamous cell carcinoma: The integration of immune checkpoint inhibitors has significantly expanded the therapeutic arsenal against esophageal squamous cell carcinoma, yet substantial heterogeneity in response underscores the limitations of current biomarkers—particularly PD-L1—as standalone predictive tools.